0001493152-22-035990.txt : 20221220 0001493152-22-035990.hdr.sgml : 20221220 20221220160533 ACCESSION NUMBER: 0001493152-22-035990 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221216 FILED AS OF DATE: 20221220 DATE AS OF CHANGE: 20221220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paulsen Gisela CENTRAL INDEX KEY: 0001807104 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 221474759 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 4 1 ownership.xml X0306 4 2022-12-16 0 0001642380 Oncocyte Corp OCX 0001807104 Paulsen Gisela 15 CUSHING IRVINE CA 92618 0 1 0 0 Former President and COO Common Stock, no par value 2022-12-01 4 D 0 175000 0 D 366500 D Option to Purchase Common Stock 3.42 2022-12-16 4 D 0 171875 0 D Common Stock 171875 203125 D Option to Purchase Common Stock 1.15 2022-12-16 4 D 0 70313 0 D Common Stock 70313 54687 D Option to Purchase Common Stock 1.15 2022-12-16 4 D 0 125000 0 D Common Stock 125000 0 D The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining restricted stock units immediately vested on December 16, 2022. The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining options immediately vested and became exercisable as of December 16, 2022. /s/ Gisela Paulsen 2022-12-20